Australia · Delayed Price · Currency is AUD Atomo Diagnostics Earnings Call Transcripts
Fiscal Year 2026
-
Q3 marked a transformative period with strong sales momentum, a strengthened balance sheet, and key regulatory wins, notably the U.S. CLIA waiver for FebriDx. The company expects significant revenue growth in Q4 and continued expansion in HIV, syphilis, and liver function testing.
-
Revenue grew 6% to nearly AUD 2.2 million, with EBITDA loss halved and cash reserves at AUD 3.5 million. Pascal device orders surged 1,600% year-over-year, and new partnerships and product developments are set to drive further growth.
-
Quarterly revenue more than doubled to AUD 1.5 million, driven by OEM Pascal and HIV self-test growth. Cash position improved, losses narrowed, and new products and OEM customers were secured, with strong outlook for further expansion.
-
Momentum continues with strong OEM and HIV self-test sales, a robust cash position, and new product launches. Regulatory progress and expanded partnerships are expected to drive further growth, especially as syphilis and Flurry products advance.
Fiscal Year 2025
-
Revenue held steady at $3.8M, with gross margin rising to over 50% and EBITDA loss narrowing by 23%. Growth in Australia and Europe offset declines in global health, while new products and OEM contracts are set to drive future expansion.
-
Strategic U.S. partnership and strong Australian HIV self-test growth drove quarterly revenue to $1.07 million, with significant capital raised and a renewed board supporting new product launches. Anticipated U.S. expansion hinges on CLIA waiver approval for FebriDx.
-
Revenue for the quarter exceeded AUD 1 million, with improved gross margins and strong growth in HIV self-testing, especially in Australia. New product development, expanded partnerships, and a successful capital raise position the business for further growth.
-
Revenue grew 7% year-over-year to over AUD 2 million, with strong HIV self-test and OEM sales, improved margins, and reduced OpEx. Expansion in developed markets and new public health channels drive growth, while funded development programs target syphilis and women's health diagnostics.
-
Q2 FY25 saw strong revenue growth, major government orders, and grant funding for new test development. Cash position improved, with expansion in Australia, Europe, and new product launches underway. Focus remains on HIV and syphilis self-testing and scaling through strategic partnerships.
-
Strong demand for HIV self-tests in Australia and Europe drove revenue growth, supported by government funding and new product launches. Cost reductions improved margins, and a major grant will accelerate syphilis test development, targeting large unmet needs in sexual health.
Fiscal Year 2024
-
The meeting highlighted strong revenue growth, cost reductions, and strategic expansion in HIV and syphilis testing, with a focus on product innovation and global market penetration. Shareholder engagement influenced governance and remuneration changes, and all resolutions were put to vote.
-
Revenue nearly doubled year-on-year, driven by strong HIV self-test and OEM growth, with gross margin and cash burn both improving. Expansion into major pharmacy and public health channels, plus new partnerships and regulatory approvals, position the business for further growth.
-
Q4 FY 2024 saw strong HIV self-test sales, major government funding in Australia, and expanded retail presence in Europe. Revenue rose to AUD 4.09 million for the year, with reduced costs and a solid cash position. OEM and development deals are expected to drive further growth.